Skip to main content

Table 3 Characteristics of subjects of the cohort 3

From: Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Case

Sex

Age (years)

Clinical diagnosis

MMSE

CSF p-tau181 (pg/ml)

Plasma p-tau181 (pg/ml)

1

M

86

AD

17

63.5

0.1057

2

F

70

AD

23

96.0

0.3785

3

F

88

AD

20

51.7

0.1063

4

F

86

VaD

18

39.3

0.0783

5

F

75

AD

18

103.0

0.2774

6

M

76

AD

5

117.0

0.1797

7

F

76

AD

4

88.0

0.1057

8

F

85

AD

12

57.0

0.1162

9

F

68

PD

30

28.8

0.0629

10

F

82

VaD

18

71.8

0.0763

11

F

76

AD

24

67.6

0.1636

  1. MMSE Mini-mental state examination, AD Alzheimer’s disease, VaD Vascular dementia, PD Parkinson’s disease